AMHR2 and ovarian carcinoma: Furthermore, the Chauvin group, collaborating with the Jackson Laboratory, developed Amhr2-CreERT2 mice (Strain #:037056) by the CRISPR/Cas9-mediated approach, which has been explored in determining the fate of cancer-associated mesothelial cells in ovarian cancer upon Amhr2 induction by crossing with the ROSA26mTmG mouse line [150].